Zingo is a drug owned by Powder Pharmaceuticals Inc. It is protected by 7 US drug patents filed from 2013 to 2016. Out of these, 3 drug patents are active and 4 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 28, 2035. Details of Zingo's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9370622 | Devices and methods for delivering particles |
Sep, 2035
(10 years from now) | Active |
| US9358338 | Particle cassettes and processes therefor |
Apr, 2035
(10 years from now) | Active |
| US8540665 | Particle cassettes and processes therefor |
Oct, 2029
(4 years from now) | Active |
| US6004286 | Particle delivery |
Mar, 2017
(7 years ago) |
Expired
|
| US6881200 | Needleless syringe using super sonic gas flow for particle delivery |
Jun, 2016
(8 years ago) |
Expired
|
| US5899880 | Needleless syringe using supersonic gas flow for particle delivery |
May, 2016
(8 years ago) |
Expired
|
| US5630796 | Method of delivering powder transdermally with needless injector |
May, 2014
(10 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Zingo's patents.
Latest Legal Activities on Zingo's Patents
Given below is the list of recent legal activities going on the following patents of Zingo.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Maintenance Fee Reminder Mailed Critical | 12 Feb, 2024 | US9370622 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 05 Mar, 2021 | US8540665 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 03 Jul, 2019 | US9370622 |
| Recordation of Patent Grant Mailed Critical | 21 Jun, 2016 | US9370622 |
| Patent Issue Date Used in PTA Calculation Critical | 21 Jun, 2016 | US9370622 |
| Issue Notification Mailed Critical | 01 Jun, 2016 | US9370622 |
| Dispatch to FDC | 24 May, 2016 | US9370622 |
| Application Is Considered Ready for Issue Critical | 20 May, 2016 | US9370622 |
| Issue Fee Payment Verified Critical | 20 May, 2016 | US9370622 |
| Issue Fee Payment Received Critical | 20 May, 2016 | US9370622 |
FDA has granted several exclusivities to Zingo. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Zingo, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Zingo.
Exclusivity Information
Zingo holds 1 exclusivities. All of its exclusivities have expired in 2012. Details of Zingo's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jan 08, 2012 |
US patents provide insights into the exclusivity only within the United States, but Zingo is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zingo's family patents as well as insights into ongoing legal events on those patents.
Zingo's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zingo's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Sep 28, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zingo Generic API suppliers:
Lidocaine Hydrochloride is the generic name for the brand Zingo. 46 different companies have already filed for the generic of Zingo, with Hospira having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zingo's generic
Alternative Brands for Zingo
Zingo which is used for providing local anesthesia with the delivery of powdered lidocaine hydrochloride monohydrate., has several other brand drugs using the same active ingredient (Lidocaine Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Thea Pharma |
| |
| Vyteris |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Lidocaine Hydrochloride, Zingo's active ingredient. Check the complete list of approved generic manufacturers for Zingo
About Zingo
Zingo is a drug owned by Powder Pharmaceuticals Inc. It is used for providing local anesthesia with the delivery of powdered lidocaine hydrochloride monohydrate. Zingo uses Lidocaine Hydrochloride as an active ingredient. Zingo was launched by Powder Pharms in 2007.
Approval Date:
Zingo was approved by FDA for market use on 16 August, 2007.
Active Ingredient:
Zingo uses Lidocaine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Lidocaine Hydrochloride ingredient
Treatment:
Zingo is used for providing local anesthesia with the delivery of powdered lidocaine hydrochloride monohydrate.
Dosage:
Zingo is available in system form for intradermal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.5MG | SYSTEM | Prescription | INTRADERMAL |